Zacks: Brokerages Anticipate BeyondSpring (BYSI) Will Post Earnings of -$0.76 Per Share

Equities analysts expect BeyondSpring (NASDAQ:BYSI) to post ($0.76) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for BeyondSpring’s earnings, with the highest EPS estimate coming in at ($0.73) and the lowest estimate coming in at ($0.79). The business is expected to report its next quarterly earnings report on Friday, April 27th.

On average, analysts expect that BeyondSpring will report full-year earnings of ($4.41) per share for the current year. For the next fiscal year, analysts forecast that the firm will post earnings of ($3.71) per share, with EPS estimates ranging from ($4.53) to ($2.89). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow BeyondSpring.

How to Become a New Pot Stock Millionaire

BYSI has been the topic of several analyst reports. Maxim Group set a $52.00 price target on shares of BeyondSpring and gave the stock a “buy” rating in a research note on Thursday, December 14th. HC Wainwright set a $60.00 price target on shares of BeyondSpring and gave the stock a “buy” rating in a research note on Thursday, March 1st. Zacks Investment Research raised shares of BeyondSpring from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Finally, Seaport Global Securities initiated coverage on shares of BeyondSpring in a research note on Tuesday, December 5th. They set a “buy” rating and a $56.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $54.50.

BeyondSpring stock traded down $0.42 during trading on Thursday, reaching $26.38. 7,867 shares of the company traded hands, compared to its average volume of 16,850. BeyondSpring has a 12-month low of $18.56 and a 12-month high of $48.49.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate BeyondSpring (BYSI) Will Post Earnings of -$0.76 Per Share” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3299665/zacks-brokerages-anticipate-beyondspring-bysi-will-post-earnings-of-0-76-per-share.html.

About BeyondSpring

BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.

Get a free copy of the Zacks research report on BeyondSpring (BYSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

LeMaitre Vascular  Issues Q2 Earnings Guidance
LeMaitre Vascular Issues Q2 Earnings Guidance
PRCoin  Market Capitalization Hits $18,688.00
PRCoin Market Capitalization Hits $18,688.00
Creatio  Trading 7.1% Higher  This Week
Creatio Trading 7.1% Higher This Week
Cherokee  versus J.Jill  Financial Analysis
Cherokee versus J.Jill Financial Analysis
Head to Head Comparison: Allegheny Technologies  & Synalloy
Head to Head Comparison: Allegheny Technologies & Synalloy
$49.78 Million in Sales Expected for FranklinCovey  This Quarter
$49.78 Million in Sales Expected for FranklinCovey This Quarter


© 2006-2018 Ticker Report. Google+.